Skip to main content
Premium Trial:

Request an Annual Quote

Buoyed by CAT Payment, Stratagene Says Q4 Revenue Surged 153 Percent; Profit Grew 18 Percent

NEW YORK, March 8 (GenomeWeb News) - Stratagene yesterday reported a 153-percent surge in revenues and an 18-percent increase in profit for the fourth quarter.


Stratagene's revenues for the three months ended Dec.31, 2005, jumped to $57.1 million from $22.6 million year over year. The company said that driving the results was a one-time receipt of $34.1 million from Cambridge Antibody Technology as part of Abbott Laboratories' Humira drug developemt.


Excluding this one-time revenue item, Stratagene said that fourth-quarter revenue increased 2.1 percent to $23 million.


R&D expenses increased 43 percent to $3.9 million for the fourth quarter from $2.7 million for the same period in 2004, Stratagene said. It attributed the rise to additional investments in the development of biology-focused pathway-analysis software.


The company's net income grew to $2 million from $1.7 million in the year-ago period.


Stratagene had approximately $35 million in cash and cash equivalents as of Dec. 31.

The Scan

Booster Push

New data shows a decline in SARS-CoV-2 vaccine efficacy over time, which the New York Times says Pfizer is using to argue its case for a booster, even as the lower efficacy remains high.

With Help from Mr. Fluffington, PurrhD

Cats could make good study animals for genetic research, the University of Missouri's Leslie Lyons tells the Atlantic.

Man Charged With Threatening to Harm Fauci, Collins

The Hill reports that Thomas Patrick Connally, Jr., was charged with making threats against federal officials.

Nature Papers Present Approach to Find Natural Products, Method to ID Cancer Driver Mutations, More

In Nature this week: combination of cryogenic electron microscopy with genome mining helps uncover natural products, driver mutations in cancer, and more.